Linneo Health and Alcaliber have announced an expanded medicinal cannabis offering by Linneo Health to include industrial cannabis derivatives.
The announcement follows the issuance of EU-GMP certification for the industrial processing of cannabis derivatives to Alcaliber. The certification has been provided by the Spanish Agency of Medicines and Medical Products (Agencia Española de Medicamentos y Productos Sanitarios – AEMPS).
Under the terms of an exclusive CDMO agreement with Alcaliber, Linneo Health now adds the capabilities to supply APIs and medicinal finished dosage forms, such as THC and standardised cannabis extracts, in addition to its existing EU-GMP certified medicinal cannabis flowers.
Read more: Linneo Health explores trends in medical cannabis
CEO of Linneo Health, Don Bellamy, said: “Our ability to supply industrial derivatives to the highest quality, in addition to our existing expertise in the cultivation and delivery of cannabis flowers to our partners, marks a major expansion in our portfolio and further cements our position as a global leader in the field.
“As the medicinal cannabis market evolves globally, alongside a changing landscape of regulatory and legal reforms, Linneo Health is primed to maintain its leadership position with a broad portfolio offering and a complete service to our customers.”
Alcaliber’s new GMP certification allows for an important expansion in Linneo Health’s medicinal product offering, and ensures that Linneo´s commitment to deliver cannabis products of the highest GMP standards is extended into cannabis extracts.
CEO of Alcaliber, José Antonio de la Puente, said: “Adding full cannabis industrial derivatives, from APIs to standardized extracts, is a great milestone for our company. Bringing our experience of more than 90 years in the extraction of active substances from herbal plants is a differential asset in the complex pharmaceutical cannabis industry.
“Our commitment to the highest standards of quality and innovation, combined with our focus on continuous improvement, underpins our new family of products.”
Linneo Health offers its customers experience in the research, cultivation and supply of medicinal cannabis, leveraging a heritage of leadership and know-how in the production of strictly regulated pharmaceutical products.
Beyond its pharmaceutical-grade cannabis flower growing at its facilities in Southern Spain, Linneo Health gains access to Alcaliber´s 12,000 tonnes of annual processing capacity.
Alcaliber’s mission is to produce and develop natural extracts and APIs to the highest standard, helping the pharmaceutical industry to improve the quality of life of millions of people around the world.
[activecampaign form=31]
